Survival
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Frontiers in Immunology 2024 January 8 [Link] Luana Calabrò, Giuseppe Bronte, Federica Grosso, Luigi Cerbone, Angelo Delmonte, Fabio Nicolini, Massimiliano Mazza, Anna Maria Di Giacomo, Alessia Covre, Maria Fortunata Lofiego, Lucio Crinò, Michele Maio Abstract Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the…
Read MoreImpact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma
Journal of Thoracic Disease 2023 December 30 [Link] Douglas Z Liou, Yoyo Wang, Prasha Bhandari, Joseph B Shrager, Natalie S Lui, Leah M Backhus, Mark F Berry Abstract Background: Modern treatment guidelines recommend multimodal therapy with at least chemotherapy and surgery for patients with potentially resectable epithelioid mesothelioma. This study evaluated guideline compliance for patients…
Read MoreThe knockdown of stathmin with si-RNA inhibits invasion of mesothelioma
Tissue and Cell 2024 January 5 [Link] Asude Aksoy, Asuman Varoglu, Ebru Etem Onalan, Ahmet Tektemur, Gokhan Artas, Mustafa Koc, Muharrem Cakmak, Siyami Aydin, Murat Kilic, Mustafa Ulas Abstract Background: To investigate the mechanism of action of stathmin1 (STMN1) in mesothelioma (MSM) and whether it has any role in its treatment. Methods: STMN1 expression was…
Read MoreExtended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesothelioma
JTCVS Open 2023 September 14 [Link] Kenichi Okubo, Hironori Ishibashi, Ryo Wakejima, Shunichi Baba, Ayaka Asakawa, Hiroshi Seshima Abstract Objective: To evaluate the efficacy of multimodality treatment including extended pleurectomy/decortication (P/D) and hyperthermic intraoperative chemotherapy (HIOC) with cisplatin for malignant pleural mesothelioma (MPM), we investigated the pharmacokinetics of platinum, adverse events after HIOC, and survival…
Read MorePD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma
Frontiers in Oncology 2023 December 4 [Link] Alejandro Avilés-Salas, Luis Cabrera-Miranda, Norma Hernández-Pedro, Diana Sofía Vargas-Lías, Suraj Samtani, Wendy Muñoz-Montaño, Daniel Motola-Kuba, Luis Corrales-Rodríguez, Claudio Martín, Andrés F Cardona, Cittim B Palomares-Palomares, Oscar Arrieta Abstract Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant…
Read MoreClinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma
Radiotherapy and Oncology 2023 December 15 [Link] Jacob Y Shin, Michael Offin, Charles B Simone, Zhigang Zhang, Annemarie F Shepherd, Abraham J Wu, Narek Shaverdian, Daphna Y Gelblum, Daniel R Gomez, Jennifer L Sauter, Michelle S Ginsberg, Prasad S Adusumilli, Valerie W Rusch, Marjorie G Zauderer, Andreas Rimner Abstract Background: The objective of this study…
Read MoreImpact of hyperthermic intrathoracic chemotherapy (HITHOC) during resection of pleural mesothelioma on patient survival
Journal of Thoracic Diseases 2023 November [Link] Irmina A Elliott, Hao He, Natalie S Lui, Douglas Z Liou, Brandon A Guenthart, Joseph B Shrager, Mark F Berry, Leah M Backhus Abstract Background: Pleural mesothelioma (PM) is rare but portends a poor prognosis. Multimodal treatment, including aggressive surgical resection, may offer the best chance of treatment…
Read MoreAnalysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…
Read MoreLAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
BMC Cancer 2023 December 7 [Link] Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, Etsuko Tagaya Abstract Background: Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs…
Read MoreCombined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using…
Read More